JP2006524227A5 - - Google Patents

Download PDF

Info

Publication number
JP2006524227A5
JP2006524227A5 JP2006506588A JP2006506588A JP2006524227A5 JP 2006524227 A5 JP2006524227 A5 JP 2006524227A5 JP 2006506588 A JP2006506588 A JP 2006506588A JP 2006506588 A JP2006506588 A JP 2006506588A JP 2006524227 A5 JP2006524227 A5 JP 2006524227A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
medicament according
independently
unsubstituted
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006506588A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006524227A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2004/001429 external-priority patent/WO2004084796A2/en
Publication of JP2006524227A publication Critical patent/JP2006524227A/ja
Publication of JP2006524227A5 publication Critical patent/JP2006524227A5/ja
Pending legal-status Critical Current

Links

JP2006506588A 2003-03-28 2004-03-29 フラビウイルス科ウイルス感染の治療のための化合物 Pending JP2006524227A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45863503P 2003-03-28 2003-03-28
PCT/IB2004/001429 WO2004084796A2 (en) 2003-03-28 2004-03-29 Compounds for the treatment of flaviviridae infections

Publications (2)

Publication Number Publication Date
JP2006524227A JP2006524227A (ja) 2006-10-26
JP2006524227A5 true JP2006524227A5 (https=) 2007-05-24

Family

ID=33098273

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006506588A Pending JP2006524227A (ja) 2003-03-28 2004-03-29 フラビウイルス科ウイルス感染の治療のための化合物

Country Status (10)

Country Link
US (1) US20050049204A1 (https=)
EP (1) EP1626692A4 (https=)
JP (1) JP2006524227A (https=)
CN (1) CN1980678A (https=)
AU (1) AU2004224575A1 (https=)
BR (1) BRPI0408846A (https=)
CA (1) CA2529311A1 (https=)
MX (1) MXPA05010419A (https=)
RU (1) RU2005133093A (https=)
WO (1) WO2004084796A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EP1736478B1 (en) 2000-05-26 2015-07-22 IDENIX Pharmaceuticals, Inc. Methods and compositions for treating flaviviruses and pestiviruses
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
CN1678326A (zh) 2002-06-28 2005-10-05 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2'－c－甲基－3'－o－l－缬氨酸酯核糖呋喃基胞苷
LT1576138T (lt) 2002-11-15 2017-06-26 Idenix Pharmaceuticals Llc 2`-šakoti nukleozidai derinyje su interferonu ir flaviviridae mutacija
AU2003300901A1 (en) 2002-12-12 2004-06-30 Idenix (Cayman) Limited Process for the production of 2'-branched nucleosides
US20090270431A1 (en) * 2005-10-19 2009-10-29 The University Of Georgia Research Foundation Cyclopentenol Nucleoside Compounds Intermediates for their Synthesis and Methods of Treating Viral Infections
AU2007286754A1 (en) * 2006-08-25 2008-02-28 Viropharma Incorporated Identification and characterization of HCV replicon variants with reduced susceptibility to HCV-796, and methods related thereto
CA2663618A1 (en) * 2006-09-11 2008-06-05 Southern Research Institute Azole nucleosides and use as inhibitors of rna and dna viral polymerases
GB2471806B (en) * 2008-04-03 2012-12-19 Spring Bank Pharmaceuticals Inc Compositions and methods for treating viral infections
WO2009152589A1 (en) 2008-06-17 2009-12-23 Universidade Federal De Minas Gerais-Ufmg Use of paf receptor for treating infections caused by flaviviridae
WO2014186435A2 (en) 2013-05-14 2014-11-20 University Of Georgia Research Foundation, Inc. Compositions and methods for reducing neointima formation
WO2020072931A2 (en) * 2018-10-04 2020-04-09 Octagon Therapeutics Inc. Pre-activated nucleoside impdh inhibitors as anti-infective drugs
WO2021110148A1 (zh) * 2019-12-06 2021-06-10 南京明德新药研发有限公司 siRNA缀合物、双链siRNA缀合物及其盐和应用
US20230123911A1 (en) * 2020-01-31 2023-04-20 Octagon Therapeutics, Inc. Modulation of immune cells
TWI879977B (zh) * 2020-06-10 2025-04-11 大陸商正大天晴藥業集團股份有限公司 雙鏈siRNA類似物的共軛物
JP7821128B2 (ja) * 2020-06-11 2026-02-26 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド 二本鎖ｓｉＲＮＡ類似体のコンジュゲート
WO2023155909A1 (zh) * 2022-02-18 2023-08-24 南京明德新药研发有限公司 三氮唑核苷类似物及其作为嵌入基团的应用
CN116808058A (zh) * 2023-07-25 2023-09-29 徐州医科大学 Pyrazofurin在制备治疗戊型肝炎疾病药物中的应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE29835E (en) * 1971-06-01 1978-11-14 Icn Pharmaceuticals 1,2,4-Triazole nucleosides
US3798209A (en) * 1971-06-01 1974-03-19 Icn Pharmaceuticals 1,2,4-triazole nucleosides
US4211771A (en) * 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
GB1414841A (en) * 1972-02-11 1975-11-19 Syntex Inc 2,5-anhydro-dalloses derivatives thereof and c-glycosylnucleosides derived therefrom
US3960836A (en) * 1974-07-22 1976-06-01 Eli Lilly And Company Acylated derivatives of pyrazofurin and process for their preparation
US5102883A (en) * 1989-10-31 1992-04-07 Du Pont Merck Pharmaceutical Company Pyrimidine biosynthesis inhibitors useful as immunosuppressive agents
ZA931934B (en) * 1992-03-18 1993-03-18 Us Bioscience Compostitions of N-(phosphonoacetyl)-L-aspartic acid and methods of their use as broad spectrum antivirals
GB9226729D0 (en) * 1992-12-22 1993-02-17 Wellcome Found Therapeutic combination
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
US5767097A (en) * 1996-01-23 1998-06-16 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
US20020137696A1 (en) * 1996-01-23 2002-09-26 Robert Tam Specific modulation of TH1/TH2 cytokine expression by ribavirin in activated T-lymphocytes
PL187439B1 (pl) * 1996-01-23 2004-07-30 Icn Pharmaceuticals Zastosowanie rybawiryny
US6150337A (en) * 1996-01-23 2000-11-21 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by Ribavirin in activated T-lymphocytes
US6455690B1 (en) * 1996-10-16 2002-09-24 Robert Tam L-8-oxo-7-propyl-7,8-dihydro-(9H)-guanosine
US6509320B1 (en) * 1996-10-16 2003-01-21 Icn Pharmaceuticals, Inc. Purine L-nucleosides, analogs and uses thereof
ATE238328T1 (de) * 1996-10-16 2003-05-15 Ribapharm Inc Monozyklische l-nukleoside, analoga und ihre anwendungen
BR9714349A (pt) * 1996-10-16 2000-11-14 Icn Pharmaceuticals L-nucleosìdeos purina, seus análogos e utilizacões dos mesmos
US6887707B2 (en) * 1996-10-28 2005-05-03 University Of Washington Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA
NZ507848A (en) * 1996-10-28 2005-01-28 Univ Washington Method of increasing the mutation rate of a virus in a non-human by administering an RNA nucleoside analogue to a virally infected cell
PE20000066A1 (es) * 1997-12-22 2000-02-09 Schering Corp Formas de dosificacion solida de ribavirina administrables oralmente y proceso de fabricacion
US6423695B1 (en) * 1998-01-13 2002-07-23 Ribapharm, Inc. Cytokine related treatments of disease
WO1999043691A1 (en) * 1998-02-25 1999-09-02 Emory University 2'-fluoronucleosides
AU766597B2 (en) * 1998-05-15 2003-10-16 Schering Corporation Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having chronic hepatitis C infection
US6833361B2 (en) * 1998-05-26 2004-12-21 Ribapharm, Inc. Nucleosides having bicyclic sugar moiety
TR200101085T2 (tr) * 1998-10-16 2001-08-21 Schering Corporation Kronik hepatit C enfeksiyonlu hastalarda algılanabilir HCV-RNA'nın yok edilmesi için birleşik ribavirin-interferon alfa tedavisi
MY125300A (en) * 1999-02-26 2006-07-31 Inst Of Molecular And Cell Biology Synergistic combination for treatment of viral-mediated diseases
US6455508B1 (en) * 2000-02-15 2002-09-24 Kanda S. Ramasamy Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides
US7056895B2 (en) * 2000-02-15 2006-06-06 Valeant Pharmaceuticals International Tirazole nucleoside analogs and methods for using same
US6495677B1 (en) * 2000-02-15 2002-12-17 Kanda S. Ramasamy Nucleoside compounds
KR20030005197A (ko) * 2000-02-18 2003-01-17 샤이어 바이오켐 인코포레이티드 뉴클레오시드유도체를 이용한 플라비바이러스 감염의 치료또는 예방 방법
EP1964569A3 (en) * 2000-04-13 2009-07-22 Pharmasset, Inc. 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of viral infections
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EP1736478B1 (en) * 2000-05-26 2015-07-22 IDENIX Pharmaceuticals, Inc. Methods and compositions for treating flaviviruses and pestiviruses
US6815542B2 (en) * 2000-06-16 2004-11-09 Ribapharm, Inc. Nucleoside compounds and uses thereof
US20030008841A1 (en) * 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
EP2180064A3 (en) * 2000-10-18 2010-08-11 Pharmasset, Inc. Multiplex quantification of nucleic acids in diseased cells
WO2002032920A2 (en) * 2000-10-18 2002-04-25 Pharmasset Limited Modified nucleosides for treatment of viral infections and abnormal cellular proliferation
SK286630B6 (sk) * 2001-01-22 2009-02-05 Merck & Co., Inc. Nukleozidové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie
US7105499B2 (en) * 2001-01-22 2006-09-12 Merck & Co., Inc. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
GB0112617D0 (en) * 2001-05-23 2001-07-18 Hoffmann La Roche Antiviral nucleoside derivatives
GB0114286D0 (en) * 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
US20040006002A1 (en) * 2001-09-28 2004-01-08 Jean-Pierre Sommadossi Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside
EP1435974A4 (en) * 2001-09-28 2006-09-06 Idenix Cayman Ltd METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEPATITIS C VIRUS USING 4 'MODIFIED NUCLEOSIDES
JP2005522443A (ja) * 2002-02-14 2005-07-28 フアーマセツト・リミテツド 改変フッ素化ヌクレオシド類似体
CN1678326A (zh) * 2002-06-28 2005-10-05 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2'－c－甲基－3'－o－l－缬氨酸酯核糖呋喃基胞苷
WO2004013300A2 (en) * 2002-08-01 2004-02-12 Pharmasset Inc. Compounds with the bicyclo[4.2.1]nonane system for the treatment of flaviviridae infections
US20040067877A1 (en) * 2002-08-01 2004-04-08 Schinazi Raymond F. 2', 3'-Dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections

Similar Documents

Publication Publication Date Title
JP2006524227A5 (https=)
MXPA05005379A (es) Tioureas de arilo sustituidas y compuestos relacionados; inhibidores de duplicacion viral.
Sredni et al. The immunomodulator AS101 administered orally as a chemoprotective and radioprotective agent
JP2005506352A5 (https=)
JP2005533824A5 (https=)
JP2004519469A5 (https=)
KR20160128305A (ko) Hbv 감염의 치료를 위한 병용 요법
UA92746C2 (en) Thiazole compounds and methods of use
RU2005133093A (ru) Соединения для лечения флавивирусных инфекций
EA200602130A1 (ru) Замещенные арилацилтиомочевины и родственные соединения; ингибиторы репликации вирусов
RU2008139195A (ru) Замещенные арилсульфанамиды как противовирусные средства
RU2010154173A (ru) Режим введения нитрокатехолов
EP1494659B1 (en) Pharmaceutical composition comprising an alpha-ketoalkanoic acid ester or -amide and lactic acid or a lactic acid salt
RU2001113268A (ru) Сочетанная терапия рибавирином и интерфероном α для удаления определяемой рнк вируса гепатита с у пациентов с хроническим гепатитом с
RU2005133665A (ru) Применение производных 10-гидрокси-10,11-дигидрокарбамазепина для лечения аффективных расстройств
JP2005527575A5 (https=)
RU2006104024A (ru) Каппа-агонисты, в особенности для лечения и/или профилактики синдрома раздраженной толстой кишки
RU2008112181A (ru) Применение конденсированных производных имидазола для лечения заболеваний, опосредованных рецептором ccr3
ES2272383T3 (es) Uso de un agente que mejora la funcion astrocitica para el tratamiento de la enfermedad de parkison.
JP5786714B2 (ja) 神経障害性疼痛の治療剤又は予防剤
PT1556027E (pt) Aminoácido modificado 5-cnac para a inibição de agregação de plaquetas
KR20070012522A (ko) 면역조절제 화합물로의 호흡기 바이러스 감염의 치료 및예방
KR20100016512A (ko) 심근경색증 치료를 위한 철 킬레이터의 용도
US20110117211A1 (en) Method of Treating or Preventing Tissue Deterioration, Injury or Damage Due to Disease of Mucosa
JP2006516576A5 (https=)